WT1 peptide immunotherapy for cancer in children and young adults

Pediatric Blood and Cancer

Volumn 55, Issue 2, 2010, Pages 352-355

  Hashii, Yoshiko ^a   Sato, Emiko ^a   Ohta, Hideaki ^a   Oka, Yoshihiro ^a   Sugiyama, Haruo ^a   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Children; Vaccination; WT1 peptide; Young adults

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; LIPOSARCOMA; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SYNOVIAL SARCOMA; VACCINATION;

ADOLESCENT; CHILD; ERYTHEMA; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; LEUKEMIA; MALE; NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINATION; WT1 PROTEINS; YOUNG ADULT;

EID: 77955104115     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22522     Document Type: Article

References (15)

1. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90:194-204. (Pubitemid 29112320)
2. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 1996;87:2878-2884.
3. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267-2278.
4. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-1171. (Pubitemid 34517654)
5. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-5337.
6. Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003;78:56-61.
7. Tsuboi A, Oka Y, Osaki T, et al. WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases. Microbiol Immunol 2004;48:175-184.
8. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-13890.
9. Iiyama T, Udaka K, Takeda S, et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007;51:519-530.
10. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108:963-971.
11. Ohta H, Hashii Y, Yoneda A, et al. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: A case report. Pediatr Hematol Oncol 2009;26:74-83.
12. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002;51:614-620. (Pubitemid 35440514)
13. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-2765. (Pubitemid 29493949)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
15. Kawakami M, Oka Y, Tsuboi A, et al. Clinical and immuno-logic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007;85:426-429.